Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2005-07

AUTHORS

J.F.R. Robertson, A. Howell, V.A. Gorbunova, T. Watanabe, T. Pienkowski, M.R. Lichinitser

ABSTRACT

There is a need for new endocrine agents that lack cross-resistance with currently available treatments to extend the endocrine treatment window and delay the need for cytotoxic chemotherapy. This retrospective analysis evaluated the response of postmenopausal patients with previously untreated metastatic/locally advanced breast cancer to further endocrine treatment following progression on first-line fulvestrant or tamoxifen. Patients received fulvestrant 250 mg (intramuscular injection every 28 days) plus matching tamoxifen placebo (once daily), or tamoxifen 20 mg (orally once daily) plus matching fulvestrant placebo (every 28 days) in a double-blind, randomized, phase III trial. Treatment continued until disease progression or withdrawal, when further endocrine therapy was initiated (at the treating physician's discretion). Information regarding subsequent therapies and responses was obtained by follow-up questionnaire. Two-hundred-and-forty-five questionnaires were returned (from 587 patients), 149 of which yielded follow-up data on patients receiving second-line endocrine therapy following fulvestrant (n=83) and tamoxifen (n=66). Second-line therapy produced objective responses (OR) in 6/44 (13.6%) and clinical benefit (CB) in 25/44 (56.8%) patients who had CB with fulvestrant and produced OR in 5/41 (12.2%) patients and CB in 27/41 (65.8%) patients who had CB with first-line tamoxifen. For patients deriving no CB from trial therapy, second-line therapy produced OR in 3/39 (7.7%) and CB in 15/39 (38.5%) patients in the fulvestrant group and OR in 4/25 (16.0%) and CB in 12/25 (48.0%) patients in the tamoxifen group. Results from this questionnaire-based study suggest that postmenopausal women with advanced breast cancer who respond to first-line fulvestrant or tamoxifen retain sensitivity to subsequent endocrine therapy. More... »

PAGES

169-174

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10549-004-4776-0

DOI

http://dx.doi.org/10.1007/s10549-004-4776-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1031540377

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/15986127


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents, Hormonal", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aromatase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Resistance, Neoplasm", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Estradiol", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Medroxyprogesterone Acetate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Megestrol Acetate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Metastasis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Postmenopause", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Retrospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Salvage Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tamoxifen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Nottingham City Hospital", 
          "id": "https://www.grid.ac/institutes/grid.412920.c", 
          "name": [
            "Unit of Surgery, City Hospital, NG5 1PB, Nottingham, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Robertson", 
        "givenName": "J.F.R.", 
        "id": "sg:person.07764637207.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Christie Hospital", 
          "id": "https://www.grid.ac/institutes/grid.415720.5", 
          "name": [
            "Christie Hospital, Manchester, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Howell", 
        "givenName": "A.", 
        "id": "sg:person.01005610111.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005610111.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Sciences", 
          "id": "https://www.grid.ac/institutes/grid.466123.4", 
          "name": [
            "Cancer Research Center of Russian Academy of Medical Sciences, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gorbunova", 
        "givenName": "V.A.", 
        "id": "sg:person.0632667636.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632667636.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "International University of Health and Welfare", 
          "id": "https://www.grid.ac/institutes/grid.411731.1", 
          "name": [
            "International University of Health and Welfare, Tochigi, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Watanabe", 
        "givenName": "T.", 
        "id": "sg:person.012704333734.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012704333734.02"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Centrum Onkologii, im M Sklodowskiej-Curie, Warsaw, Poland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pienkowski", 
        "givenName": "T.", 
        "id": "sg:person.01372307334.38", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372307334.38"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Medical Sciences", 
          "id": "https://www.grid.ac/institutes/grid.466123.4", 
          "name": [
            "Cancer Research Center of Russian Academy of Medical Sciences, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lichinitser", 
        "givenName": "M.R.", 
        "id": "sg:person.01025064345.67", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025064345.67"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1023/a:1023983032625", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001709392", 
          "https://doi.org/10.1023/a:1023983032625"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/(sici)1097-0142(19980915)83:6<1142::aid-cncr13>3.0.co;2-5", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1005407624"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2004.02.112", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008461339"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1359-6349(04)90867-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1021532015"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(97)11423-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033560955"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0959-8049(00)00041-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050959091"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.10.057", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2002.10.058", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1064203148"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1074881954", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1077661065", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2005-07", 
    "datePublishedReg": "2005-07-01", 
    "description": "There is a need for new endocrine agents that lack cross-resistance with currently available treatments to extend the endocrine treatment window and delay the need for cytotoxic chemotherapy. This retrospective analysis evaluated the response of postmenopausal patients with previously untreated metastatic/locally advanced breast cancer to further endocrine treatment following progression on first-line fulvestrant or tamoxifen. Patients received fulvestrant 250 mg (intramuscular injection every 28 days) plus matching tamoxifen placebo (once daily), or tamoxifen 20 mg (orally once daily) plus matching fulvestrant placebo (every 28 days) in a double-blind, randomized, phase III trial. Treatment continued until disease progression or withdrawal, when further endocrine therapy was initiated (at the treating physician's discretion). Information regarding subsequent therapies and responses was obtained by follow-up questionnaire. Two-hundred-and-forty-five questionnaires were returned (from 587 patients), 149 of which yielded follow-up data on patients receiving second-line endocrine therapy following fulvestrant (n=83) and tamoxifen (n=66). Second-line therapy produced objective responses (OR) in 6/44 (13.6%) and clinical benefit (CB) in 25/44 (56.8%) patients who had CB with fulvestrant and produced OR in 5/41 (12.2%) patients and CB in 27/41 (65.8%) patients who had CB with first-line tamoxifen. For patients deriving no CB from trial therapy, second-line therapy produced OR in 3/39 (7.7%) and CB in 15/39 (38.5%) patients in the fulvestrant group and OR in 4/25 (16.0%) and CB in 12/25 (48.0%) patients in the tamoxifen group. Results from this questionnaire-based study suggest that postmenopausal women with advanced breast cancer who respond to first-line fulvestrant or tamoxifen retain sensitivity to subsequent endocrine therapy.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10549-004-4776-0", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "92"
      }
    ], 
    "name": "Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant", 
    "pagination": "169-174", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "9640d82eee63df55f206baa1ed6d1c19727ff0b5675e02e89f8fb5a1aa3bc0fc"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "15986127"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8111104"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10549-004-4776-0"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1031540377"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10549-004-4776-0", 
      "https://app.dimensions.ai/details/publication/pub.1031540377"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-10T13:17", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000001_0000000264/records_8659_00000513.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007%2Fs10549-004-4776-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10549-004-4776-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10549-004-4776-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10549-004-4776-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10549-004-4776-0'


 

This table displays all metadata directly associated to this object as RDF triples.

216 TRIPLES      21 PREDICATES      57 URIs      39 LITERALS      27 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10549-004-4776-0 schema:about N174707315c6b47319cddff4640ad4dae
2 N18e1674803204e40b818883fc4d55381
3 N501af97a054443bcab993057a95a52b0
4 N50986943b37648dbbb2bfd60ffe1aef4
5 N64a7d11607e04179806614fb97128131
6 N67f9ed2b40c34abd985f8b0e38a59e26
7 N80c7c2361d054ed6a17e18d4eba4b2de
8 N8357d37679c14ad8be4d649bf976da3f
9 N83799e38226b4ce69c094e52c50fe158
10 N8fa5485f2fb74ed6b5752f69515d64ae
11 Na172a3e2b741481e9f154e775c9ce269
12 Na9dc76e6e06246b389ae1efaff6b4842
13 Naeba0f11bf3e4d4f85ad5638abd57228
14 Naf90e8686c634becb63a9a46a98d46b6
15 Nb38d0426c2514e4386693f9e8a7c4a88
16 Nec9db0739f1e4120aa04e5fb86aa8a2e
17 Nf24d66a41384414a9b3bd044152937af
18 Nfa658a5ee1304acea7c46b82fe145b76
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author N3ee179272aff4222843c285b2596836d
22 schema:citation sg:pub.10.1023/a:1023983032625
23 https://app.dimensions.ai/details/publication/pub.1074881954
24 https://app.dimensions.ai/details/publication/pub.1077661065
25 https://doi.org/10.1002/(sici)1097-0142(19980915)83:6<1142::aid-cncr13>3.0.co;2-5
26 https://doi.org/10.1016/s0140-6736(97)11423-4
27 https://doi.org/10.1016/s0959-8049(00)00041-1
28 https://doi.org/10.1016/s1359-6349(04)90867-1
29 https://doi.org/10.1200/jco.2002.10.057
30 https://doi.org/10.1200/jco.2002.10.058
31 https://doi.org/10.1200/jco.2004.02.112
32 schema:datePublished 2005-07
33 schema:datePublishedReg 2005-07-01
34 schema:description There is a need for new endocrine agents that lack cross-resistance with currently available treatments to extend the endocrine treatment window and delay the need for cytotoxic chemotherapy. This retrospective analysis evaluated the response of postmenopausal patients with previously untreated metastatic/locally advanced breast cancer to further endocrine treatment following progression on first-line fulvestrant or tamoxifen. Patients received fulvestrant 250 mg (intramuscular injection every 28 days) plus matching tamoxifen placebo (once daily), or tamoxifen 20 mg (orally once daily) plus matching fulvestrant placebo (every 28 days) in a double-blind, randomized, phase III trial. Treatment continued until disease progression or withdrawal, when further endocrine therapy was initiated (at the treating physician's discretion). Information regarding subsequent therapies and responses was obtained by follow-up questionnaire. Two-hundred-and-forty-five questionnaires were returned (from 587 patients), 149 of which yielded follow-up data on patients receiving second-line endocrine therapy following fulvestrant (n=83) and tamoxifen (n=66). Second-line therapy produced objective responses (OR) in 6/44 (13.6%) and clinical benefit (CB) in 25/44 (56.8%) patients who had CB with fulvestrant and produced OR in 5/41 (12.2%) patients and CB in 27/41 (65.8%) patients who had CB with first-line tamoxifen. For patients deriving no CB from trial therapy, second-line therapy produced OR in 3/39 (7.7%) and CB in 15/39 (38.5%) patients in the fulvestrant group and OR in 4/25 (16.0%) and CB in 12/25 (48.0%) patients in the tamoxifen group. Results from this questionnaire-based study suggest that postmenopausal women with advanced breast cancer who respond to first-line fulvestrant or tamoxifen retain sensitivity to subsequent endocrine therapy.
35 schema:genre research_article
36 schema:inLanguage en
37 schema:isAccessibleForFree false
38 schema:isPartOf N068252c9bc484a5a869acbf38bd3cf54
39 Nf819c9ef8b62403b8c8083e609fe8400
40 sg:journal.1092777
41 schema:name Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant
42 schema:pagination 169-174
43 schema:productId N040fd65c84374e03b2e9b93302361ed8
44 N0aa4c7bfd7134307939465cf216d1c12
45 Na5238bb3983441b3b006616a55e25e93
46 Na9ba16e7db984b5c966fcfffb10a92c9
47 Nf09e6558227a4c7eaa1749e5796355d1
48 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031540377
49 https://doi.org/10.1007/s10549-004-4776-0
50 schema:sdDatePublished 2019-04-10T13:17
51 schema:sdLicense https://scigraph.springernature.com/explorer/license/
52 schema:sdPublisher N14f9e06da388402eb6a9c4f6432186ed
53 schema:url http://link.springer.com/10.1007%2Fs10549-004-4776-0
54 sgo:license sg:explorer/license/
55 sgo:sdDataset articles
56 rdf:type schema:ScholarlyArticle
57 N040fd65c84374e03b2e9b93302361ed8 schema:name readcube_id
58 schema:value 9640d82eee63df55f206baa1ed6d1c19727ff0b5675e02e89f8fb5a1aa3bc0fc
59 rdf:type schema:PropertyValue
60 N068252c9bc484a5a869acbf38bd3cf54 schema:volumeNumber 92
61 rdf:type schema:PublicationVolume
62 N0aa4c7bfd7134307939465cf216d1c12 schema:name dimensions_id
63 schema:value pub.1031540377
64 rdf:type schema:PropertyValue
65 N14f9e06da388402eb6a9c4f6432186ed schema:name Springer Nature - SN SciGraph project
66 rdf:type schema:Organization
67 N174707315c6b47319cddff4640ad4dae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
68 schema:name Female
69 rdf:type schema:DefinedTerm
70 N18e1674803204e40b818883fc4d55381 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
71 schema:name Medroxyprogesterone Acetate
72 rdf:type schema:DefinedTerm
73 N27a6b61c19d44fba90689421e6becdab rdf:first sg:person.0632667636.81
74 rdf:rest Nf5f0d4c1ed5e4b0eb33038d156c8954b
75 N3ee179272aff4222843c285b2596836d rdf:first sg:person.07764637207.20
76 rdf:rest Ncfec7ebdb92f4b20977c31722ddae5e4
77 N501af97a054443bcab993057a95a52b0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
78 schema:name Antineoplastic Agents, Hormonal
79 rdf:type schema:DefinedTerm
80 N50986943b37648dbbb2bfd60ffe1aef4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
81 schema:name Breast Neoplasms
82 rdf:type schema:DefinedTerm
83 N54c6252f09724e108eac0c071c445e60 rdf:first sg:person.01025064345.67
84 rdf:rest rdf:nil
85 N64a7d11607e04179806614fb97128131 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
86 schema:name Postmenopause
87 rdf:type schema:DefinedTerm
88 N67f9ed2b40c34abd985f8b0e38a59e26 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
89 schema:name Drug Resistance, Neoplasm
90 rdf:type schema:DefinedTerm
91 N80c7c2361d054ed6a17e18d4eba4b2de schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Treatment Outcome
93 rdf:type schema:DefinedTerm
94 N8357d37679c14ad8be4d649bf976da3f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Adult
96 rdf:type schema:DefinedTerm
97 N83799e38226b4ce69c094e52c50fe158 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Aged
99 rdf:type schema:DefinedTerm
100 N8fa5485f2fb74ed6b5752f69515d64ae schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
101 schema:name Tamoxifen
102 rdf:type schema:DefinedTerm
103 Na172a3e2b741481e9f154e775c9ce269 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
104 schema:name Retrospective Studies
105 rdf:type schema:DefinedTerm
106 Na5238bb3983441b3b006616a55e25e93 schema:name pubmed_id
107 schema:value 15986127
108 rdf:type schema:PropertyValue
109 Na9ba16e7db984b5c966fcfffb10a92c9 schema:name nlm_unique_id
110 schema:value 8111104
111 rdf:type schema:PropertyValue
112 Na9dc76e6e06246b389ae1efaff6b4842 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
113 schema:name Estradiol
114 rdf:type schema:DefinedTerm
115 Naeba0f11bf3e4d4f85ad5638abd57228 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Aromatase Inhibitors
117 rdf:type schema:DefinedTerm
118 Naf90e8686c634becb63a9a46a98d46b6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Middle Aged
120 rdf:type schema:DefinedTerm
121 Nb38d0426c2514e4386693f9e8a7c4a88 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Megestrol Acetate
123 rdf:type schema:DefinedTerm
124 Nc4aff8c0cf174c5599bbd695ef5c726d schema:name Centrum Onkologii, im M Sklodowskiej-Curie, Warsaw, Poland
125 rdf:type schema:Organization
126 Ncc5a5e819e784433bf79965eb9c5f557 rdf:first sg:person.01372307334.38
127 rdf:rest N54c6252f09724e108eac0c071c445e60
128 Ncfec7ebdb92f4b20977c31722ddae5e4 rdf:first sg:person.01005610111.35
129 rdf:rest N27a6b61c19d44fba90689421e6becdab
130 Nec9db0739f1e4120aa04e5fb86aa8a2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
131 schema:name Humans
132 rdf:type schema:DefinedTerm
133 Nf09e6558227a4c7eaa1749e5796355d1 schema:name doi
134 schema:value 10.1007/s10549-004-4776-0
135 rdf:type schema:PropertyValue
136 Nf24d66a41384414a9b3bd044152937af schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Salvage Therapy
138 rdf:type schema:DefinedTerm
139 Nf5f0d4c1ed5e4b0eb33038d156c8954b rdf:first sg:person.012704333734.02
140 rdf:rest Ncc5a5e819e784433bf79965eb9c5f557
141 Nf819c9ef8b62403b8c8083e609fe8400 schema:issueNumber 2
142 rdf:type schema:PublicationIssue
143 Nfa658a5ee1304acea7c46b82fe145b76 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Neoplasm Metastasis
145 rdf:type schema:DefinedTerm
146 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
147 schema:name Medical and Health Sciences
148 rdf:type schema:DefinedTerm
149 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
150 schema:name Oncology and Carcinogenesis
151 rdf:type schema:DefinedTerm
152 sg:journal.1092777 schema:issn 0167-6806
153 1573-7217
154 schema:name Breast Cancer Research and Treatment
155 rdf:type schema:Periodical
156 sg:person.01005610111.35 schema:affiliation https://www.grid.ac/institutes/grid.415720.5
157 schema:familyName Howell
158 schema:givenName A.
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01005610111.35
160 rdf:type schema:Person
161 sg:person.01025064345.67 schema:affiliation https://www.grid.ac/institutes/grid.466123.4
162 schema:familyName Lichinitser
163 schema:givenName M.R.
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01025064345.67
165 rdf:type schema:Person
166 sg:person.012704333734.02 schema:affiliation https://www.grid.ac/institutes/grid.411731.1
167 schema:familyName Watanabe
168 schema:givenName T.
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012704333734.02
170 rdf:type schema:Person
171 sg:person.01372307334.38 schema:affiliation Nc4aff8c0cf174c5599bbd695ef5c726d
172 schema:familyName Pienkowski
173 schema:givenName T.
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01372307334.38
175 rdf:type schema:Person
176 sg:person.0632667636.81 schema:affiliation https://www.grid.ac/institutes/grid.466123.4
177 schema:familyName Gorbunova
178 schema:givenName V.A.
179 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0632667636.81
180 rdf:type schema:Person
181 sg:person.07764637207.20 schema:affiliation https://www.grid.ac/institutes/grid.412920.c
182 schema:familyName Robertson
183 schema:givenName J.F.R.
184 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07764637207.20
185 rdf:type schema:Person
186 sg:pub.10.1023/a:1023983032625 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001709392
187 https://doi.org/10.1023/a:1023983032625
188 rdf:type schema:CreativeWork
189 https://app.dimensions.ai/details/publication/pub.1074881954 schema:CreativeWork
190 https://app.dimensions.ai/details/publication/pub.1077661065 schema:CreativeWork
191 https://doi.org/10.1002/(sici)1097-0142(19980915)83:6<1142::aid-cncr13>3.0.co;2-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1005407624
192 rdf:type schema:CreativeWork
193 https://doi.org/10.1016/s0140-6736(97)11423-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033560955
194 rdf:type schema:CreativeWork
195 https://doi.org/10.1016/s0959-8049(00)00041-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050959091
196 rdf:type schema:CreativeWork
197 https://doi.org/10.1016/s1359-6349(04)90867-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1021532015
198 rdf:type schema:CreativeWork
199 https://doi.org/10.1200/jco.2002.10.057 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203147
200 rdf:type schema:CreativeWork
201 https://doi.org/10.1200/jco.2002.10.058 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064203148
202 rdf:type schema:CreativeWork
203 https://doi.org/10.1200/jco.2004.02.112 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008461339
204 rdf:type schema:CreativeWork
205 https://www.grid.ac/institutes/grid.411731.1 schema:alternateName International University of Health and Welfare
206 schema:name International University of Health and Welfare, Tochigi, Japan
207 rdf:type schema:Organization
208 https://www.grid.ac/institutes/grid.412920.c schema:alternateName Nottingham City Hospital
209 schema:name Unit of Surgery, City Hospital, NG5 1PB, Nottingham, UK
210 rdf:type schema:Organization
211 https://www.grid.ac/institutes/grid.415720.5 schema:alternateName The Christie Hospital
212 schema:name Christie Hospital, Manchester, UK
213 rdf:type schema:Organization
214 https://www.grid.ac/institutes/grid.466123.4 schema:alternateName Department of Medical Sciences
215 schema:name Cancer Research Center of Russian Academy of Medical Sciences, Moscow, Russia
216 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...